Numerous studies have undertaken ex vivo drug sensitivity testing in AML and come up with compelling drugs for clinical investigation, such as inhibitors of BCL-2, PI3K, HSP90, JAK, MEK, CDK, and BET [220,221,222,223,224,225]. The gene discussed is BCL2; the disease is acute myeloid leukemia.